Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

92.08

+0.68

(+0.74%)

At close: 04:03PM EDT

92.10

+0.02

(+0.02%)

After hours:

07:51PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Short-term KST

View all chart patterns

Performance Outlook

Previous Close	91.40
Open	91.55
Bid	91.80 x 1400
Ask	92.12 x 800
Day's Range	91.50 - 93.02
52 Week Range	70.89 - 95.72
Volume	8,828,912
Avg. Volume	10,539,798

Market Cap	233.264B
Beta (5Y Monthly)	0.32
PE Ratio (TTM)	13.99
EPS (TTM)	6.58
Earnings Date	Oct 27, 2022
Forward Dividend & Yield	2.76 (3.03%)
Ex-Dividend Date	Sep 14, 2022
1y Target Est	100.68

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

7% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MRK

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Merck & Company, Inc.
Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
Rating
Fair Value
Economic Moat
10 days agoArgus Research

All

Benzinga
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using two monoclonal antibodies. Following a systematic review and meta-analysis, WHO recommended two monoclonal antibody treatments, Ebanga (Ansuvimab, mAb114) and Inmazeb (REGN-EB3). Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Inmazeb became the first treatment for the ebola virus when it received FDA approval in October 2020. Merck & Co Inc's (NYSE: MRK)
- WHO recommends use of two antibody drugs against Ebola
  Reuters
- Aarvik Therapeutics Announces Validation of Novel Tetravalent Antibody Platform
  Business Wire
Zacks
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Investor's Business Daily
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.